Suppression of Breast Cancer Cell Growth by Her2-Reduced AR Serine 81 Phosphorylation

10.4077/CJP.2016.BAE416

Pao-Hsuan Huang；Hsin-Yi Wang；Chen-Chuan Huang；Yueh-Tsung Lee；Chia-Herng Yue；Mei-Chih Chen；Ho Lin

androgen receptor ； breast cancer ； Her2, Lapatinib ； MDA-MB-453 cell line

The Chinese Journal of Physiology

59卷4期（2016 / 08 / 31）

232 - 239

英文

Breast cancer is a hormone-related carcinoma and the most commonly diagnosed malignancy in women. Although Her-2, estrogen receptor (ER), and progesterone receptor (PR) are the major diagnostic markers and therapeutic targets to breast cancer, searching for additional molecular targets remains an important issue and one of the candidates is androgen receptor (AR). AR has been shown expressed in 70% breast cancer patients and connects to low recurrence and high survival rate. Our previous study demonstrates that Ser81 phosphorylation of AR in prostate cancer cells is critical for its protein stability modulated by human epidermal growth factor receptor-2 (Her2). The aim of this study is to investigate the influence of Her2 and AR in prolifer-ation of breast cancer cell line, MDA-MB-453. The data show that AR which was activated by synthetic androgen R1881 suppressed the proliferation of MDAMB- 453 cells. Notably, AR activation decreased the protein levels of cell growth-related proteins, including cyclin A, cyclin B, and early growth response protein 1 (Egr1), while cell-cycle inhibitor protein p27 was increased. Besides, Heregulin (HRG)-induced Her2 activation decreased the AR protein levels and its Ser81 phosphorylation. Her2 small molecular inhibitor, Lapatinib, dose-dependently suppressed cell proliferation while the levels of phospho-Ser81 AR and p27 protein were increased. Phospho-Ser81 AR was also increased after Her2 knockdown. Specifically, the influence of phospho-Ser81 AR by Lapatinib was primarily found in the nucleus of MDA-MD-453 cells, where the cell proliferation might directly be interfered. In conclusion, our findings indicate that Her2 might negatively regulate AR phosphorylation/activation and contribute to regulate the proliferation of MDA-MB 453 cells.

1. Zhao, S.,Gai, X.,Wang, Y.,Liang, W.,Gao, H.,Zhang, K.,Wang, H.,Liu, Y.,Wang, J.,Ma, R.(2015).Diagnostic values of carcinoembryonic antigen, cancer antigen 15-3 and cancer antigen 125 levels in nipple discharge.Chinese J. Physiol.,58,385-392.
   連結：
2. Agoff, S.N.,Swanson, P.E.,Linden, H.,Hawes, S.E.,Lawton, T.J.(2003).Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations.Am. J. Clin. Pathol.,120,725-731.
3. Baron, V.,Duss, S.,Rhim, J.,Mercola, D.(2003).Antisense to the early growth response-1 gene (Egr-1) inhibits prostate tumor development in TRAMP mice.Ann. N. Y. Acad. Sci.,1002,197-216.
4. Chen, S.,Xu, Y.,Yuan, X.,Bubley, G.J.,Balk, S.P.(2006).Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.Proc. Natl. Acad. Sci. USA,103,15969-15974.
5. de Longueville, F.,Lacroix, M.,Barbuto, A.M.,Bertholet, V.,Gallo, D.,Larsimont, D.,Marcq, L.,Zammatteo, N.,Boffe, S.,Leclercq, G.,Remacle, J.(2005).Molecular characterization of breast cancer cell lines by a low-density microarray.Int. J. Oncol.,27,881-892.
6. Doane, A.S.,Danso, M.,Lal, P.,Donaton, M.,Zhang, L.,Hudis, C.,Gerald, W.L.(2006).An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.Oncogene,25,3994-4008.
7. Dowsett, M.,Dunbier, A.K.(2008).Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.Clin. Cancer Res.,14,8019-8026.
8. Farmer, P.,Bonnefoi, H.,Becette, V.,Tubiana-Hulin, M.,Fumoleau, P.,Larsimont, D.,Macgrogan, G.,Bergh, J.,Cameron, D.,Goldstein, D.,Duss, S.,Nicoulaz, A.L.,Brisken, C.,Fiche, M.,Delorenzi, M.,Iggo, R.(2005).Identification of molecular apocrine breast tumours by microarray analysis.Oncogene,24,4660-4671.
9. Goldhirsch, A.,Glick, J.H.,Gelber, R.D.,Coates, A.S.,Senn, H.J.(2001).Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.J. Clin. Oncol.,19,3817-3827.
10. Gordon, V.,Bhadel, S.,Wunderlich, W.,Zhang, J.,Ficarro, S.B.,Mollah, S.A.,Shabanowitz, J.,Hunt, D.F.,Xenarios, I.,Hahn, W.C.,Conaway, M.,Carey, M.F.,Gioeli, D.(2010).CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.Mol. Endocrinol.,24,2267-2280.
11. Hall, J.M.,Couse, J.F.,Korach, K.S.(2001).The multifaceted mechanisms of estradiol and estrogen receptor signaling.J. Biol. Chem.,276,36869-36872.
12. Hsu, F.N.,Chen, M.C.,Chiang, M.C.,Lin, E.,Lee, Y.T.,Huang, P.H.,Lee, G.S.,Lin, H.(2011).Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.J. Biol. Chem.,286,33141-33149.
13. Hsu, F.N.,Yang, M.S.,Lin, E.,Tseng, C.F.,Lin, H.(2011).The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.Am. J. Physiol. Endocrinol. Metab.,300,E902-E908.
14. Huang, P.H.,Huang, C.Y.,Chen, M.C.,Lee, Y.T.,Yue, C.H.,Wang, H.Y.,Lin, H.(2013).Emodin and aloe-emodin suppress breast cancer cell proliferation through er alpha inhibition.Evid. Based Complement. Alternat. Med.,2013,376123.
15. Kuenen-Boumeester, V.,Van der Kwast, T.H.,Claassen, C.C.,Look, M.P.,Liem, G.S.,Klijn, J.G.,Henzen-Logmans, S.C.(1996).The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.Eur. J. Cancer,32A,1560-1565.
16. Kuo, P.L.,Chen, Y.H.,Chen, T.C.,Shen, K.H.,Hsu, Y.L.(2011).CXCL5/ENA78 increased cell migration and epithelial-tomesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.J. Cell. Physiol.,226,1224-1231.
17. Lee, Y.T.,Guo, J.C.,Lin, C.H.,Wu, H.S.,Liu, Y.H.,Lai, Y.S.,Lin, H.(2014).Involvement of the target proteins in the investigation to prognostic model for breast cancer.Adapt. Med.,6,148-156.
18. Liu, Y.,Majumder, S.,McCall, W.,Sartor, C.I.,Mohler, J.L.,Gregory, C.W.,Earp, H.S.,Whang, Y.E.(2005).Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.Cancer Res.,65,3404-3409.
19. Ma, W.W.,Adjei, A.A.(2009).Novel agents on the horizon for cancer therapy.CA Cancer J. Clin.,59,111-137.
20. Mangelsdorf, D.J.,Thummel, C.,Beato, M.,Herrlich, P.,Schutz, G.,Umesono, K.,Blumberg, B.,Kastner, P.,Mark, M.,Chambon, P.,Evans, R.M.(1995).The nuclear receptor superfamily: the second decade.Cell,83,835-839.
21. Mariani, G.,Fasolo, A.,De Benedictis, E.,Gianni, L.(2009).Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.Nat. Clin. Pract. Oncol.,6,93-104.
22. Naderi, A.,Hughes-Davies, L.(2008).A functionally significant crosstalk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.Neoplasia,10,542-548.
23. Ni, M.,Chen, Y.,Lim, E.,Wimberly, H.,Bailey, S.T.,Imai, Y.,Rimm, D.L.,Liu, X.S.,Brown, M.(2011).Targeting androgen receptor in estrogen receptor-negative breast cancer.Cancer Cell,20,119-131.
24. Park, S.,Koo, J.,Park, H.S.,Kim, J.H.,Choi, S.Y.,Lee, J.H.,Park, B.W.,Lee, K.S.(2010).Expression of androgen receptors in primary breast cancer.Ann. Oncol.,21,488-492.
25. Sachdev, J.C.,Jahanzeb, M.(2012).Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.Clin. Breast Cancer,12,19-29.
26. Salah, Z.,Maoz, M.,Pizov, G.,Bar-Shavit, R.(2007).Transcriptional regulation of human protease-activated receptor 1: a role for the early growth response-1 protein in prostate cancer.Cancer Res.,67,9835-9843.
27. Tan, D.,Zhang, J.,Tang, P.,Huang, J.,Walker, A.(2013).Association of D5 Stat5a induced breast cancer cell migration with increased H3K27 trimethylation and down-regulated expression of e-cadherin gene.Adapt. Med.,5,189-195.
28. Thorpe, S.M.,Rose, C.(1986).Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.Cancer Surv.,5,505-525.
29. Walker, R.A.(1999).Oestrogen receptor and its potential role in breast cancer development.J. Pathol.,188,229-230.
30. Wang, Y.,He, X.,Yu, Q.,Eng, C.(2013).Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas.Hum. Mol. Genet.,22,2263-2272.
31. Wang, Y.,Romigh, T.,He, X.,Tan, M.H.,Orloff, M.S.,Silverman, R.H.,Heston, W.D.,Eng, C.(2011).Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.Oncogene,30,4327-4338.

1. Tsung-Ying Yang,Mei-Chih Chen,Ho Lin,G. M. Shazzad Hossain Prince(2019).Mechanistic Insight of Cyclin-Dependent Kinase 5 in Modulating Lung Cancer Growth.The Chinese Journal of Physiology,62(6),231-240.